Back to directory
Strategic Investor
Thousand Oaks, CA
Amgen
Biotechnology giant whose Quantinuum Series A investment reflects the strategic value of quantum chemistry simulation for drug discovery.
Amgen participated in Quantinuum's January 2024 Series A. The biotech industry has been one of the most consistent strategic investor categories in commercial quantum computing, driven by the long-term promise of quantum chemistry simulation for molecular modeling and drug discovery applications.
Quantinuum's InQuanto chemistry software product is specifically positioned for these use cases, and Amgen's investment reflects both portfolio exposure and strategic alignment with quantum chemistry capability development.
Colorado portfolio
strategicbiotechquantum chemistryQuantinuum Series A